Chemotherapy with mitomycin C and capecitabine in patients with advanced colorectal cancer pretreated with irinotecan and oxaliplatin

Lorenza Rimassa, Giuseppe Gullo, Carlo Carnaghi, Giovanni Abbadessa, Monica Zuradelli, Maria Chiara Tronconi, Tiziana Pressiani, Armando Santoro

Research output: Contribution to journalArticlepeer-review

Abstract

Aims and background: To assess the activity and tolerability of the combination of mitomycin C and capecitabine in patients with metastatic colorectal cancer after failure of irinotecan-and oxaliplatin-containing regimens. Methods: We retrospectively reviewed 28 patients with pretreated advanced colorectal cancer who had been treated with mitomycin C, 6 mg/m 2 on day 1, and capecitabine, 1,900 mg/m2 on days 1-14, every 3 weeks. Tumor assessment was performed every 3 cycles, toxicity assessed at each cycle. Results: Main patient characteristics were median age, 61 years (range, 35-73); male/female ratio, 16/12; single metastatic site involvement, 5/28 (18%); ≥3 metastatic sites, 10/28 (36%). Ninety-six courses of therapy were given (median number, 3; range, 1-9). Twenty-six patients were assessable for response, and all were assessable for toxicity. There was 1 partial response (4%) and 12 had stable disease (43%). Median time to progression was 2 months (range, 1-9) and median overall survival was 6 months (range, 1-29+), with a 1-year overall survival rate of 25%. The regimen was very well tolerated without significant hematological toxicity. Conclusions: Our results are disappointing. Despite the good safety profile, they do not support further investigation or the routine use of this regimen in this setting.

Original languageEnglish
Pages (from-to)285-289
Number of pages5
JournalTumori
Volume92
Issue number4
Publication statusPublished - Jul 2006

Keywords

  • Advanced colorectal cancer
  • Capecitabine
  • Mitomycin C

ASJC Scopus subject areas

  • Cancer Research

Fingerprint

Dive into the research topics of 'Chemotherapy with mitomycin C and capecitabine in patients with advanced colorectal cancer pretreated with irinotecan and oxaliplatin'. Together they form a unique fingerprint.

Cite this